Literature DB >> 35282934

Platinum-Based Chemotherapy 'Rechallenge' in Advanced Non-ovarian Solid Malignancies.

J Hack1, S J Crabb2.   

Abstract

Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Carboplatin; chemotherapy; cisplatin; rechallenge; resistance

Mesh:

Substances:

Year:  2022        PMID: 35282934     DOI: 10.1016/j.clon.2022.02.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.925


  1 in total

1.  Comprehensive analysis of the glutathione S-transferase Mu (GSTM) gene family in ovarian cancer identifies prognostic and expression significance.

Authors:  Juan Zhang; Yan Li; Juan Zou; Chun-Tian Lai; Tian Zeng; Juan Peng; Wen-da Zou; Bei Cao; Dan Liu; Li-Yu Zhu; Hui Li; Yu-Kun Li
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.